Back to Clinical Trials
Phase 3Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Sponsored by Colorado Prevention Center

About this study

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

This is an international, randomized, double-blind, placebo-controlled trial of finerenone for the treatment of heart failure patients with reduced ejection fraction.

Where this study is enrolling (50)

Show all 50 locations
Who can participate

Inclusion criteria

  • ✓Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations
  • ✓Age ≥18 years or legal age of majority if \>18 years in the participant's country of residence
  • ✓Symptomatic HFrEF per protocol defined criteria
  • ✓Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment
  • ✓Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)

Exclusion criteria

  • ✕Treatment with non-steroidal MRA (nsMRA)
  • ✕Documented prior history of severe hyperkalemia in the setting of MRA use
  • ✕eGFR \< 25 mL/min/1.73m² and / or potassium \> 5.0 mmol/L
  • ✕Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days or planned
  • ✕Prior or planned heart transplant
  • ✕Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure
  • ✕Symptomatic bradycardia or second- or third-degree heart block without a pacemaker
  • ✕Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction
  • ✕Probable alternative cause of participant's HF
  • ✕Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, or moderate or potent CYP3A4 inducers
  • ✕Known hypersensitivity to the IP (active substance or excipients)
  • ✕Any other condition or therapy which would make the participant unsuitable for the study
  • ✕Concurrent or previous participation in another interventional clinical study using an investigational agent within 30 days prior to randomization

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.